


Procter & Gamble - I.P. DivisionRECEIVED
CENTRAL FAX CENTER**IMPORTANT CONFIDENTIALITY NOTICE**

MAY 03 2004

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

OFFICIAL**FACSIMILE TRANSMITTAL SHEET AND
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8****TO:** United States Patent and Trademark Office

Fax No. (703) 872-9306 Phone No. (703) 308-4710

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 30, 2004, to the above-identified facsimile number.
(Signature)**FROM:** Joan B. Cunningham

Fax No. (513) 622-3300 Phone No. (513) 622-3993

Number of Pages Including this Page: 6

Listed below are the item(s) being submitted with this Certificate of Transmission:

- 1) Fee Transmittal (1 page)
- 2) Petition for Extension of Time (1 page)
- 3) Response Under 37 CFR 1.111 (3 pgs.)
- 4)

Inventor(s): Douglas Joseph Dobrozsi

S.N.: 09/361,542

Filed: July 27, 1999

Case: 7247M

Comments:

**FEE TRANSMITTAL
for FY 2004**

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$950)**Complete if Known**

Application Number	09/361,542
Confirmation Number	5652
Filing Date	July 27, 1999
First Named Inventor	Douglas J. Dobrozs
Examiner Name	A. Fullam
Art Unit	1615
Attorney Docket No.	7247M

METHOD OF PAYMENT

1. [X] The Director is hereby authorized to charge indicated fees submitted on this form, credit any over payments, and charge any additional fee(s) during the pendency of this application to:

Deposit Account Number: 16-2480

Deposit Account Name: The Procter & Gamble Company

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Code	(S)	Fee Description	Fees Paid
1051	130	Surcharge-late filing fee or oath	<input type="checkbox"/>
1052	50	Surcharge-late provisional filing fee or cover sheet	<input type="checkbox"/>
1053	130	Non-English specification	<input type="checkbox"/>
1812	2,520	For filing a request for <i>ex parte</i> reexamination	<input type="checkbox"/>
1804	920*	Requesting publication of SIR prior to Examiner's action	<input type="checkbox"/>
1805	1,840*	Requesting publication of SIR after Examiner's action	<input type="checkbox"/>
1251	110	Extension for reply within 1 st month	<input type="checkbox"/>
1252	420	Extension for reply within 2 nd month	<input type="checkbox"/>
1253	950	Extension for reply within 3 rd month	<input checked="" type="checkbox"/>
1254	1,480	Extension for reply within 4 th month	<input type="checkbox"/>
1255	2,010	Extension for reply within 5 th month	<input type="checkbox"/>
1401	330	Notice of Appeal	<input type="checkbox"/>
1402	330	Filing a brief in support of an appeal	<input type="checkbox"/>
1403	290	Request for oral hearing	<input type="checkbox"/>
1451	1,510	Petition to institute a public use proceeding	<input type="checkbox"/>
1452	110	Petition to revive - unavoidable	<input type="checkbox"/>
1453	1,330	Petition to revive - unintentional	<input type="checkbox"/>
1501	1,330	Utility issue fee (or reissue)	<input type="checkbox"/>
1502	480	Design issue fee	<input type="checkbox"/>
1460	130	Petitions to the Commissioner	<input type="checkbox"/>
1807	50	Processing fee under 37 C.F.R. 1.17(q)	<input type="checkbox"/>
1806	180	Submission of Information Disclosure Statement	<input type="checkbox"/>
1809	770	Filing a submission after final rejection (37 CFR § 1.129(a))	<input type="checkbox"/>
1810	770	For each additional invention to be examined (37 CFR § 1.129(b))	<input type="checkbox"/>
1801	770	Request for Continued Examination (RCE)	<input type="checkbox"/>
1802	900	Request for expedited examination of a design application	<input type="checkbox"/>
1454	1330	Acceptance of unintentionally delayed claim for priority under 35 U.S.C. 119, 120, 121, or 365 (a) or (c)	<input type="checkbox"/>
Other fee (specify) _____ <input type="checkbox"/>			
Other fee (specify) _____ <input type="checkbox"/>			

SUBTOTAL (2) (\$950)

* Reduced by Basic Filing Fee Paid

SUBTOTAL(3) (\$950) []**SUBMITTED BY**

Name (Print/Type)	Joan B. Cunningham	Registration No. (Attorney/Agent)	43,962	Telephone	(513) 622-3993
Signature	<i>Joan B. Cunningham</i>			Date	April 30, 2004

+ This collection of information is required by 37 CFR 1.17. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon individual case. Any comment on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Fees/line (Revised for P&G use 9/22/2003)

Case 7247M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :
 Douglas J. Dobrozsi :
 Serial No.: 09/361,542 :
 Confirmation No.: 5652 :
 Filed: July 27, 1999 :
 Title: Oral Liquid Mucoadhesive Compositions :

RECEIVED
CENTRAL FAX CENTERGroup Art Unit: 1615
Examiner: A. Pulliam

MAY 03 2004

OFFICIALRESPONSE UNDER 37 CFR 1.111

Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Dear Sir:

In response to the October 31, 2003 Office Action in the above-identified case, please consider the following remarks.

REMARKS

Claims 36, 38-39, 41-46, and 48 remain in the present application. Claims 1-35, 37, 40, and 47 have been previously canceled. No additional claims fee is believed to be due.

Invention Synopsis

The present invention is directed to oral, liquid, aqueous, mucoretentive compositions, and a method of administering such compositions, wherein the compositions comprise colloidal particles of silicon dioxide, a select pharmaceutical active, and a citric acid.

It has been found that prolonged and improved coating and protection of components of the alimentary canal such as the stomach, esophagus, and small intestine can be achieved by incorporating a mucoadhesive material into an oral pharmaceutical composition. Unlike conventional mucoadhesive materials such as mucoadhesive polymers, the compositions of the present invention comprise a silicon dioxide which provides for highly effective mucoadhesive systems. It has also been found that when the compositions of the present invention comprise a citric acid, the solid particles of these highly effective mucoadhesive systems are consistently dispersed to result in improved stability of the systems.

Art Rejection

Claims 36, 38-39, 41-46, and 48 have been rejected under 35 U.S.C. 103 as being unpatentably obvious over the product Silicol* (manufactured by Saguna GmbH in Germany) in view of Banning et